Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.Novo’s share price is languishing about 70 percent below its peak from mid-2024, when it was Europe’s most valuable public company.